NEW YORK (GenomeWeb News) – Genomic Health said after the close of the market Wednesday that it will collaborate with OncoMed Pharmaceuticals in identifying biomarkers that can be applied to clinical development of certain OncoMed antibody cancer drugs.
OncoMed will provide Genomic Health with breast, prostate, colon, and lung tumor samples, and will include a subset of OncoMed's proprietary xenograft models derived from freshly resected human cancers. Genomic Health will use its next-generation sequencing capabilities to discover biomarkers that may help identify patients that are more likely to respond to cancer therapeutics that target the Notch, Wnt and other pathways critical to cancer stem cells.
"This collaboration supports our long-term vision and belief that molecular diagnostics are inherent for bringing quality, personalized care to all cancer patients from diagnosis through survivorship," Genomic Health Chief Medical Officer Steve Shak said in a statement.
Financial and other terms of the agreement were not disclosed.